News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
769,485 Results
Type
Article (58355)
Company Profile (611)
Press Release (710519)
Multimedia
Podcasts (94)
Webinars (13)
Section
Business (218710)
Career Advice (2835)
Deals (37917)
Drug Delivery (121)
Drug Development (86594)
Employer Resources (183)
FDA (17723)
Job Trends (16278)
News (372897)
Policy (37361)
Tag
Academia (2927)
Academic (1)
Accelerated approval (6)
Adcomms (25)
Allergies (94)
Alliances (54006)
ALS (102)
Alzheimer's disease (1483)
Antibody-drug conjugate (ADC) (156)
Approvals (17693)
Artificial intelligence (316)
Autoimmune disease (28)
Automation (16)
Bankruptcy (389)
Best Places to Work (12426)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (422)
Bladder cancer (85)
Brain cancer (31)
Breast cancer (308)
Cancer (2442)
Cardiovascular disease (204)
Career advice (2385)
Career pathing (34)
CAR-T (169)
Cell therapy (474)
Cervical cancer (22)
Clinical research (70200)
Collaboration (921)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2854)
CRISPR (48)
C-suite (268)
Cystic fibrosis (107)
Data (2348)
Decentralized trials (2)
Denatured (31)
Depression (53)
Diabetes (296)
Diagnostics (6823)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (46)
Drug discovery (138)
Drug pricing (128)
Drug shortages (32)
Duchenne muscular dystrophy (101)
Earnings (91196)
Editorial (46)
Employer branding (21)
Employer resources (157)
Events (121017)
Executive appointments (775)
FDA (19152)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (821)
Gene editing (121)
Generative AI (29)
Gene therapy (347)
GLP-1 (823)
Government (4987)
Grass and pollen (5)
Guidances (150)
Healthcare (20379)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (139)
Indications (30)
Infectious disease (3016)
Inflammatory bowel disease (157)
Inflation Reduction Act (9)
Influenza (58)
Intellectual property (102)
Interviews (502)
IPO (17346)
IRA (49)
Job creations (4327)
Job search strategy (1996)
Kidney cancer (11)
Labor market (43)
Layoffs (538)
Leadership (24)
Legal (9308)
Liver cancer (82)
Lung cancer (341)
Lymphoma (160)
Machine learning (9)
Management (63)
Manufacturing (361)
MASH (78)
Medical device (14361)
Medtech (14366)
Mergers & acquisitions (21138)
Metabolic disorders (779)
Multiple sclerosis (86)
NASH (18)
Neurodegenerative disease (107)
Neuropsychiatric disorders (31)
Neuroscience (2082)
NextGen: Class of 2025 (7354)
Non-profit (4962)
Now hiring (40)
Obesity (413)
Opinion (260)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (89)
Parkinson's disease (160)
Partnered (21)
Patents (256)
Patient recruitment (119)
Peanut (50)
People (61381)
Pharmaceutical (127)
Pharmacy benefit managers (22)
Phase I (21763)
Phase II (30685)
Phase III (23073)
Pipeline (1382)
Policy (172)
Postmarket research (3035)
Preclinical (9424)
Press Release (71)
Prostate cancer (112)
Psychedelics (34)
Radiopharmaceuticals (265)
Rare diseases (426)
Real estate (6637)
Recruiting (70)
Regulatory (25397)
Reports (49)
Research institute (2599)
Resumes & cover letters (463)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (80)
Series A (138)
Series B (94)
Service/supplier (25)
Sickle cell disease (58)
Special edition (20)
Spinal muscular atrophy (160)
Sponsored (32)
Startups (3977)
State (2)
Stomach cancer (16)
Supply chain (73)
Tariffs (53)
The Weekly (61)
Vaccines (807)
Venture capitalists (44)
Weight loss (286)
Women's health (36)
Worklife (19)
Date
Last 7 days (968)
Last 30 days (3130)
Last 365 days (34618)
2025 (12495)
2024 (37460)
2023 (42038)
2022 (53393)
2021 (58163)
2020 (57041)
2019 (50262)
2018 (38242)
2017 (35326)
2016 (35344)
2015 (41223)
2014 (35184)
2013 (30569)
2012 (32685)
2011 (33291)
2010 (31424)
Location
Africa (977)
Alabama (58)
Alaska (7)
Arizona (253)
Arkansas (14)
Asia (44601)
Australia (7465)
California (6628)
Canada (2094)
China (568)
Colorado (285)
Connecticut (302)
Delaware (166)
Europe (98509)
Florida (971)
Georgia (224)
Hawaii (1)
Idaho (60)
Illinois (601)
India (28)
Indiana (338)
Iowa (12)
Japan (176)
Kansas (111)
Kentucky (27)
Louisiana (14)
Maine (62)
Maryland (987)
Massachusetts (5037)
Michigan (233)
Minnesota (421)
Mississippi (2)
Missouri (90)
Montana (31)
Nebraska (25)
Nevada (69)
New Hampshire (68)
New Jersey (1854)
New Mexico (31)
New York (1860)
North Carolina (1100)
North Dakota (9)
Northern California (2853)
Ohio (218)
Oklahoma (15)
Oregon (45)
Pennsylvania (1457)
Puerto Rico (13)
Rhode Island (36)
South America (1365)
South Carolina (26)
South Dakota (1)
Southern California (2470)
Tennessee (107)
Texas (992)
United States (25120)
Utah (194)
Virginia (171)
Washington D.C. (71)
Washington State (602)
West Virginia (3)
Wisconsin (70)
769,485 Results for "idorsia pharmaceuticals us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
May 2, 2025
·
4 min read
Press Releases
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
April 30, 2025
·
26 min read
Press Releases
Idorsia publishes its Annual Report 2024
March 27, 2025
·
12 min read
Press Releases
Idorsia announces financial results for 2024
March 4, 2025
·
25 min read
Press Releases
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
February 26, 2025
·
4 min read
Press Releases
Idorsia publishes the resolutions for the upcoming bondholder meeting
February 12, 2025
·
6 min read
Press Releases
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
January 16, 2025
·
6 min read
Press Releases
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
May 8, 2025
·
5 min read
FDA
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Idorsia Pharmaceuticals U.S. Inc. announced today that the US Food and Drug Administration (FDA) has approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.
March 20, 2024
·
19 min read
Press Releases
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
February 26, 2025
·
3 min read
1 of 76,949
Next
